New targets, new drugs with different mechanisms, and new combination regimens are all worth trying, for example, a stronger combination: PD-1 inhibitor + targeted therapy + TACE, etc. Secondly, we have revealed good efficacy of combined immunotherapy in advanced patients, and the application of immunotherapy combination models in early and mid-stage HCC needs to be further explored, such as immunotherapy combined targeted therapy for the perioperative treatment of HCC. Here, PDCD1 is linked to hepatocellular carcinoma.